Invest Daily Pro
  • Economy
  • Investing
No Result
View All Result
  • Economy
  • Investing
No Result
View All Result
Invest Daily Pro
No Result
View All Result
Home Stocks

Is a Bold Rotation Brewing in Healthcare and Biotech? Here’s What to Watch Now

by Invest Daily Pro
June 14, 2025
in Stocks
0
Is a Bold Rotation Brewing in Healthcare and Biotech? Here’s What to Watch Now
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Catching a sector early as it rotates out of a slump is one of the more reliable ways to get ahead of an emerging trend. You just have to make sure the rotation has enough strength to follow through.

On Thursday morning, as the markets maintained a cautiously bullish tone, I checked the New Highs panel on the StockCharts Dashboard, scanning the 1-, 3-, 6-, and 9-month highs list. A clear theme emerged—biotech and healthcare stocks dominated the shorter-term highs.

Seeing strength in healthcare and biotech, I checked the Market Summary BPI panel to compare breadth across sectors. Healthcare posted a 63.93% reading—an early sign the sector may be turning higher.

Comparing the broader sector with the biotech industry, the Key Ratios – Offense vs. Defense panel showed that Biotech outperformed Healthcare by a modest 2.31% over the past three months. This panel compares the SPDR S&P Biotech ETF (XBI), which represents the biotech sector, with the broader Health Care Select Sector SPDR Fund (XLV).

Are Biotech and Healthcare Starting a Bullish Rotation?

So, are we seeing an early rotation of both industry and sector toward the upside, and could either be shaping up as an opportunity for investment? Let’s take a comparative look at both relative to the SPDR S&P 500 ETF (SPY), our broad market stand-in.

Comparing XBI and XLV to SPY: Signs of Leadership?

FIGURE 1. PERFCHARTS OF XBI, XLV, AND SPY. This is typical of what you’d see during an early-stage rotation.

This PerfCharts view shows a one-year snapshot of relative performance, with biotech lagging behind healthcare, and both trailing the SPY in negative territory. Yet XBI and XLV are showing signs of recovery, with XBI exhibiting a sharper angle of ascent.

Seasonal Strength in Healthcare and Biotech Stocks

Now here’s an interesting addition to the current analysis: what if we considered the industry and the sector from a seasonality perspective? The reason for this is that certain sectors and the industries within them tend to exhibit recurring patterns of strength or weakness during specific times of the year. If we’re seeing a potential turning point in either, could a seasonality lens offer additional insight or clarity to the analysis?

Biotech Seasonality: Strong Months for XBI

Let’s start with XBI, and notice how it’s now entering a cluster of seasonally-favorable months.

FIGURE 2. SEASONALITY CHART OF XBI. The industry is entering a cluster of seasonally strong months.

According to this 10-year seasonality chart, June, July, August, and November tend to be strong months for XBI, with positive closing rates well above 50% (see figures above each bar) and higher-than-average returns (see figures at the bottom of the bars). Among them, June and November stand out as XBI’s strongest seasonal months.

XLV Seasonality: November Still Reigns

FIGURE 3. SEASONALITY CHART OF XLV.  According to this, July is XLV’s second-strongest month after November.

XLV’s seasonal profile shares a similar pattern, with a few key differences. July emerges as XLV’s second-strongest month, boasting a close rate of 89% and an average return of 3.1%. Like XBI, November is XLV’s top month in terms of average return.

What this tells us is that the biotech industry and the broader healthcare sector have historically performed well during these periods (especially November), suggesting that seasonal strength could serve as a tailwind if the current rotation continues to build momentum.

Charting the Rotation: XBI Trend Structure Shows Some Clarity

Next, let’s take a look at their current price action, starting with a daily chart of XBI.

FIGURE 4. DAILY CHART OF XBI. Notice how the trend structure is well-defined by the Fibonacci retracement, providing clear measurements for you to gauge the subsequent directionality once the market decides which way XBI will go.

XBI’s price action shows it reversed at the 50% Fibonacci Retracement level (November high to April low). Will the bears take control, or will XBI’s near-term reaction strengthen into an uptrend, eventually pushing XBI past the 61.8% retracement level, a threshold wherein bears may fold their positions and bulls increase theirs?

In light of the latter, the Relative Strength Index (RSI) is at 61 and rising, indicating room for upside, but only under the condition that the current bullish swing maintains its trajectory.

A few actionable tips. If you’re bullish on XBI and planning to add it to your portfolio, consider the following:

  • If XBI were to pull back deeper, watch to see if it bounces near the last recent swing low area at $76.
  • If XBI reverses to the upside, expect resistance at the 61.8% Fib retracement at around $91. Also, watch the yellow-shaded zone around $94, an area of concentrated trading activity which may also act as a strong resistance zone.

If XBI rotates in a bullish fashion, these key levels can help guide your analysis.

XLV Technical Setup: Strength, But Not Yet a Breakout

Next, shift over to a daily chart of XLV. You’ll notice it’s quite different despite also exhibiting a recovery.

FIGURE 5. DAILY CHART OF XLV. Unlike the previous example, XLV’s price action is more muddled.

XLV’s recovery doesn’t appear as convincing just yet, as it still needs to clear multiple swing highs and resistance levels clustered between $139 and $141 (highlighted in green). If it manages to break above this zone, the next resistance range—shaded in yellow—sits between $148 and $150. In short, the sector proxy faces several hurdles and technical headwinds ahead.

The RSI, at 58 and rising, is nowhere near overbought territory, but it may not immediately indicate bullishness unless XLV is able to establish an uptrend. For now, it isn’t clear if that will happen, so exercise caution.

From an actionable standpoint, the current technical structure doesn’t offer a clear entry setup. That’s largely because the trend lacks a well-defined sequence of higher swing highs and higher swing lows—something you’d typically look for when establishing favorable entry and exit positions.

At the Close

If healthcare and biotech are starting to rotate higher, XBI and XLV are the charts to watch. XBI shows a stronger trend structure, while XLV still faces resistance.  With seasonality on their side, add them to your ChartLists to track key levels and price action.


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

ShareTweetPin

Related Posts

Chart Mania – 23 ATR Move in QQQ – Metals Lead 2025 – XLV Oversold – XLU Breakout – ITB Moment of Truth
Stocks

Chart Mania – 23 ATR Move in QQQ – Metals Lead 2025 – XLV Oversold – XLU Breakout – ITB Moment of Truth

July 26, 2025
Momentum Leaders Are Rotating — Here’s How to Find Them
Stocks

Momentum Leaders Are Rotating — Here’s How to Find Them

July 25, 2025
S&P 500 Breaking Out Again: What This Means for Your Portfolio
Stocks

S&P 500 Breaking Out Again: What This Means for Your Portfolio

July 25, 2025
A Wild Ride For the History Books: 2025 Mid-Year Recap
Stocks

A Wild Ride For the History Books: 2025 Mid-Year Recap

July 24, 2025
Is META Breaking Out or Breaking Down?
Stocks

Is META Breaking Out or Breaking Down?

July 24, 2025
Tech Taps the Brakes, Homebuilders Hit the Gas: See the Rotation on StockCharts Today
Stocks

Tech Taps the Brakes, Homebuilders Hit the Gas: See the Rotation on StockCharts Today

July 23, 2025
Next Post
Right to Earn Majority Interest in Highly Prospective Chilean Copper-Gold-Molybdenite Porphyry Project and Placement to raise $2.2m

Right to Earn Majority Interest in Highly Prospective Chilean Copper-Gold-Molybdenite Porphyry Project and Placement to raise $2.2m

Recommended

Wetherspoons warns of pint price rise as budget adds £60m in costs

Wetherspoons warns of pint price rise as budget adds £60m in costs

November 6, 2024
US posture in PHL’s sea dispute with China hinges on Trump’s Cabinet

US posture in PHL’s sea dispute with China hinges on Trump’s Cabinet

December 22, 2024
“Scanpack 2024 Showcases BIXOLON’s Extensive Selection of Label Printing Solutions”

“Scanpack 2024 Showcases BIXOLON’s Extensive Selection of Label Printing Solutions”

October 15, 2024
PHL AI guardrails must be in line with regional standards, focused on data

PHL AI guardrails must be in line with regional standards, focused on data

August 28, 2024
How To Maximize Value and Growth Of Business with Financial Modeling and Forecasting Services

How To Maximize Value and Growth Of Business with Financial Modeling and Forecasting Services

October 9, 2024
DoLE urged to boost job quality, not temp work

DoLE urged to boost job quality, not temp work

August 22, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 InvestDailyPro. All Rights Reserved.

    Disclaimer: InvestDailyPro.com, its managers, its employees, and assigns (collectively InvestDailyPro ) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
    The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    No Result
    View All Result
    • About us
    • Contact us
    • Home
    • Privacy Policy
    • Suspicious engagement
    • Terms & Conditions
    • Thank you

    Copyright © 2025 investdailypro.com | All Rights Reserved